Sionna’s cystic fibrosis flop sends stock down 90%, but a ‘significant positive’ for Vertex

Sionna Therapeutics has axed a cystic fibrosis add-on program after flunking a phase 2 trial, eliminating a would-be challenger to Vertex Pharmaceuticals’ empire. The biotech plans to “take actions to preserve capital while evaluating next steps.”